Brown snake venom proteins (BSV)

Brown snake venom proteins refer to the complex mixture of bioactive molecules found in the venom of the genus Pseudonaja, which are among the most lethal snakes globally. The primary clinical manifestation of envenomation is venom-induced consumptive coagulopathy (VICC), driven by potent prothrombin activator complexes that rapidly convert prothrombin to thrombin, leading to fibrinogen depletion (Isbister et al., 2006). In addition to these coagulants, the venom contains various other enzymes and toxins such as phospholipases A2 (PLA2), which can exert presynaptic neurotoxic effects by inhibiting neurotransmitter release (Kornhauser et al., 2010). Three-finger toxins (3FTxs) are also present and may interfere with nicotinic acetylcholine receptors or ion channels, although they are typically less dominant in Pseudonaja textilis than in other elapids. Other enzymatic components like hyaluronidase act as spreading factors by degrading the extracellular matrix, thereby accelerating the systemic absorption of the venom into the bloodstream. L-amino acid oxidases and serine proteases further contribute to the local tissue damage and systemic inflammatory response observed in victims. Therapeutic management of envenomation relies on the administration of specific antivenoms, which contain purified antibodies that bind and neutralize these diverse proteins (White, 2005). These antivenoms are critical for reversing the effects of VICC and preventing the progression of neurotoxicity, though they must be administered early to be most effective.

Other names

Other brown snake venom enzymes and toxinsPseudonaja venom toxinsBrown snake venom enzymesEastern brown snake toxinsPseudonaja textilis venom components

Passive immunization via antibody-mediated neutralization of venom toxins and enzymes, preventing their interaction with physiological substrates and receptors.